Abstract Data from the placebo arm of DEN-301, a phase 3 trial of the TAK-003 dengue vaccine, were evaluated in this secondary post hoc analysis to assess dengue burden. Participants were aged 4–16 years from Asia Pacific and Latin America. The primary endpoint was efficacy of TAK-003 against virologically confirmed dengue (VCD). Hospitalized VCD was a secondary endpoint. Active surveillance captured both hospitalized and non-hospitalized cases.
John Weil
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with John
Contact John, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack